Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

In Vivo CAR-T Development Service with FuNV (Fusion Nanovesicle) Technology

Q: Can FuNVs be used to target tumors other than B-cell malignancies (e.g., solid tumors)?

Absolutely. While in vivo CAR-T is proven for hematological cancers, our platform's engineering capabilities are designed for solid tumors. We utilize engineered nanovesicles (e.g., anti-PD-L1 NVs) to remodel the immunosuppressive tumor microenvironment and prevent CAR-T exhaustion, which is the primary challenge in solid tumor oncology.

Online Inquiry

Background Service What we can offer Workflow Highlights FAQs Contact

The development of in vivo CAR-T therapy continues to face persistent challenges inherited from conventional ex vivo manufacturing, including complex processes, high production costs, long turnaround times, and limited efficacy against solid tumors. Creative Biolabs' In vivo CAR-T Development with FuNVs (Fusion Nanovesicle) Technology enables precise in vivo T cell engineering via a non-viral approach, delivering customized nanovesicles directly to target cells. Our platform significantly streamlines the supply chain, reduces production costs, and enhances both safety and therapeutic outcomes in solid tumors, accelerating the translation of next-generation immunotherapies from bench to bedside.

Introduction

Fusion Nanovesicles (FuNVs) are a class of engineered virus-mimetic nanocarriers designed with surface-displayed fusogenic proteins that specifically target T cells, such as modified fusogens derived from measles or reovirus. These FuNVs enable direct cytosolic delivery of functional proteins into target cells via membrane fusion. The in vivo CAR-T development platform based on FuNVs utilizes intravenous administration of CAR protein-loaded FuNVs to efficiently reprogram T cells directly inside the living organism, generating functional CAR-T cells. This approach bypasses the complexity and high costs associated with conventional ex vivo expansion processes, while significantly reducing the risk of adverse effects such as cytokine release syndrome (CRS).

Fig.1 A simplified approach to CAR-T manufacturing: in vivo programming of T cells by fusogenic nanovesicle infusion. (OA Literature) Fig.1 In vivo generation of CAR-T cells via virus-mimetic fusion nanovesicles (FuNVs).¹

In vivo CAR-T Development with FuNVs (Fusion Nanovesicle) Technology at Creative Biolabs

Creative Biolabs' In vivo CAR-T Development with FuNVs (Fusion Nanovesicle) Technology enables the direct and safe generation of CAR-T cells inside the patient's body, eliminating reliance on traditional ex vivo cell expansion processes. Our solution accelerates research progress through superior scalability, significantly reduces the risk of CRS, and achieves precise targeting efficiency.

What We Can Offer

We offer an innovative in vivo CAR-T development platform centered on FuNVs. Our system enables the direct cytosolic delivery of CAR proteins via engineered fusogens, allowing for non-viral T cell reprogramming within the patient, and ensures precise targeting with controlled, transient expression to enhance efficacy and reduce safety risks.

Featured services of in vivo CAR-T development with FuNVs technology at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Antigen/ScFv Sequence: The sequence of the tumor-associated antigen (TAA) or the single-chain variable fragment (scFv) used for CAR targeting.
Desired CAR Gene Construct: The specific sequence of the CAR gene for encapsulation (e.g., anti-CD19, anti-BCMA, etc.).
Target Cell Line Specifications: Information on the T cell population or disease model being utilized for initial validation.

Key Steps:

Workflow of in vivo CAR-T development with FuNVs technology at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Master FuNV Cell Line: A stable, engineered cell line for scalable nanovesicle production.
Final FuNV-CAR Drug Product: Lyophilized or liquid formulation of the FuNVs containing your interested CAR gene.
Comprehensive QC and Efficacy Report: Detailed documentation covering encapsulation efficiency, T cell fusion rate, in vivo efficacy, and CRS safety data.

Key Advantages

Bespoke FuNV Engineering and Customization: Full customization of the FuNV surface, including integrating client-specific CAR constructs and novel T cell targeting ligands, to ensure optimal tropism and in vivo transduction efficiency.
Scalable, Non-Viral Manufacturing Protocols: Development of high-yield nanovesicle production protocols suitable for seamless transition from research scale to large-scale industrial manufacturing, drastically reducing COGS and logistics complexity compared to ex vivo processes.
Multi-Modal Payload Integration: Advanced capability for co-delivering the CAR gene alongside a secondary therapeutic agent (e.g., STING agonists or specific siRNA sequences) for enhanced solid tumor efficacy and Tumor Microenvironment (TME) remodeling.

FAQ

How does the FuNV platform compare to traditional viral vectors for in vivo gene delivery?

Viral vectors carry risks of immunogenicity and off-target genomic integration. Our FuNV platform is non-viral and based on a membrane fusion mechanism, which significantly mitigates these risks, offering a safer and more controllable method for delivering genetic material exclusively to the target T cell population. We encourage you to contact us for a detailed technical comparison.

Can FuNVs be used to target tumors other than B-cell malignancies (e.g., solid tumors)?

Absolutely. While in vivo CAR-T is proven for hematological cancers, our platform's engineering capabilities are designed for solid tumors. We utilize engineered nanovesicles (e.g., anti-PD-L1 NVs) to remodel the immunosuppressive tumor microenvironment and prevent CAR-T exhaustion, which is the primary challenge in solid tumor oncology.

Why Choose Us?

We directly tackle key bottlenecks in cancer immunotherapy. Our engineered nanovesicles enable non-viral, in vivo generation of CAR-T cells with enhanced safety and reduced CRS risk, superior targeting precision, multi-modal payload versatility, and unprecedented scalability, offering a transformative solution for both hematological and solid tumors.

Customer Reviews

"The application of Creative Biolabs' In vivo CAR-T Development platform incorporating FuNVs Technology has markedly enhanced the safety profile of STING agonist delivery in our study. By enabling precise localization of the therapeutic payload to the tumor microenvironment, this approach effectively circumvents the severe systemic inflammatory responses previously associated with free agonist administration." Ky Ro*.

"Utilizing Creative Biolabs' In vivo CAR-T Development with FuNVs Technology has substantially improved the commercial viability of our CAR-T initiative. The platform supports scalable, high-throughput, and non-viral cell modification, thereby enabling feasible mass production—an achievement that remained elusive with conventional methodologies." Jn Sh*.

"Through Creative Biolabs' In vivo CAR-T Development enhanced by FuNVs Technology, we have achieved multi-modal targeting capability, seamlessly integrating T cell therapy with gene silencing mechanisms. This system permits the co-delivery of CAR genes and EGFR-targeting siRNA with enzyme-activated specificity, significantly augmenting therapeutic precision." Aa Wg*.

How to Contact Us?

Ready to unlock the full potential of your pipeline? We are here to ensure your vision translates into viable, efficient, and impactful outcomes. Our team offers detailed exploratory discussions, all necessary technical dossiers, and a clear project roadmap tailored to your specific objectives.

Connect with our experts to take the first strategic step.

Reference

Zhao, Gui et al. "In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles." Science bulletin vol. 69,3 (2024): 354-366. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1016/j.scib.2023.11.055.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.